These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34212837)

  • 1. Treatment with High-Dose Prednisolone in Vigabatrin-Refractory Infantile Spasms.
    Al-Shehhi W; Chau V; Boyd J; Snead C; Sharma R; Donner E; Go C; Jain P
    Can J Neurol Sci; 2022 Jul; 49(4):532-539. PubMed ID: 34212837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infantile spasms.
    Hancock EC; Osborne JP; Edwards SW
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001770. PubMed ID: 23740534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigabatrin and high-dose prednisolone therapy for patients with West syndrome.
    Ko A; Youn SE; Chung HJ; Kim SH; Lee JS; Kim HD; Kang HC
    Epilepsy Res; 2018 Sep; 145():127-133. PubMed ID: 29966811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms.
    Yuskaitis CJ; Mytinger JR; Baumer FM; Zhang B; Liu S; Samanta D; Hussain SA; Yozawitz EG; Keator CG; Joshi C; Singh RK; Bhatia S; Bhalla S; Shellhaas R; Harini C;
    Neurology; 2022 Nov; 99(22):e2494-e2503. PubMed ID: 36038267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial.
    O'Callaghan FJK; Edwards SW; Alber FD; Cortina Borja M; Hancock E; Johnson AL; Kennedy CR; Likeman M; Lux AL; Mackay MT; Mallick AA; Newton RW; Nolan M; Pressler R; Rating D; Schmitt B; Verity CM; Osborne JP;
    Lancet Child Adolesc Health; 2018 Oct; 2(10):715-725. PubMed ID: 30236380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol.
    Eliyan Y; Heesch J; Alayari A; Rajaraman RR; Sankar R; Hussain SA
    Pediatr Neurol; 2019 Oct; 99():16-22. PubMed ID: 31331669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.
    O'Callaghan FJ; Edwards SW; Alber FD; Hancock E; Johnson AL; Kennedy CR; Likeman M; Lux AL; Mackay M; Mallick AA; Newton RW; Nolan M; Pressler R; Rating D; Schmitt B; Verity CM; Osborne JP;
    Lancet Neurol; 2017 Jan; 16(1):33-42. PubMed ID: 27838190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium.
    Demarest ST; Shellhaas RA; Gaillard WD; Keator C; Nickels KC; Hussain SA; Loddenkemper T; Patel AD; Saneto RP; Wirrell E; Sánchez Fernández I; Chu CJ; Grinspan Z; Wusthoff CJ; Joshi S; Mohamed IS; Stafstrom CE; Stack CV; Yozawitz E; Bluvstein JS; Singh RK; Knupp KG;
    Epilepsia; 2017 Dec; 58(12):2098-2103. PubMed ID: 29105055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.
    Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP
    Lancet; 2004 Nov 13-19; 364(9447):1773-8. PubMed ID: 15541450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of West syndrome].
    Cvitanović-Sojat L; Gjergja R; Sabol Z; Hajnzić TF; Sojat T
    Acta Med Croatica; 2005; 59(1):19-29. PubMed ID: 15813352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms.
    Askalan R; Mackay M; Brian J; Otsubo H; McDermott C; Bryson S; Boyd J; Snead C; Roberts W; Weiss S
    J Child Neurol; 2003 Mar; 18(3):165-70. PubMed ID: 12731640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trials.
    Osborne JP; Edwards SW; Alber FD; Hancock E; Johnson AL; Kennedy CR; Likeman M; Lux AL; Mackay M; Mallick A; Newton RW; Nolan M; Pressler R; Rating D; Schmitt B; Verity CM; O'Callaghan FK
    Eur J Paediatr Neurol; 2023 Jan; 42():110-116. PubMed ID: 36621063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Felbamate in the treatment of refractory epileptic spasms.
    Hussain SA; Asilnejad B; Heesch J; Navarro M; Ji M; Shrey DW; Rajaraman RR; Sankar R
    Epilepsy Res; 2020 Mar; 161():106284. PubMed ID: 32058261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients.
    Djuric M; Kravljanac R; Tadic B; Mrlješ-Popovic N; Appleton RE
    Epilepsia; 2014 Dec; 55(12):1918-25. PubMed ID: 25377998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.
    Sánchez Fernández I; Amengual-Gual M; Barcia Aguilar C; Romeu A; Sheikh T; Torres A; Chao J; Jonas R; Gaínza-Lein M; Harini C; Douglass L
    Epilepsia; 2023 Mar; 64(3):630-640. PubMed ID: 36600453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prioritizing Hormone Therapy Over Vigabatrin as the First Treatment for Infantile Spasms: A Quality Improvement Initiative.
    Mytinger JR; Parker W; Rust SW; Ahrens SM; Albert DVF; Beatty CW; Chrisman J; Clark DJ; Debs A; Denney D; Karn M; Herbst J; Ostendorf AP; Taylor MC; Twanow JDE; Vidaurre J; Patel AD
    Neurology; 2022 Nov; 99(19):e2171-e2180. PubMed ID: 36038276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodevelopmental and epilepsy outcomes of patients with infantile spasms treated in a tertiary care center.
    Bashiri FA; Al-Sehemi MA; Hamad MH; Alshammari NR; Aljumah MA; Kentab A; Salih MA
    Neurosciences (Riyadh); 2021 Jan; 26(1):21-25. PubMed ID: 33530039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of treatments for infantile spasms.
    Nabbout R
    Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epileptic spasms related to neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and high dose prednisolone therapy.
    Sakpichaisakul K; Boonkrongsak R; Lertbutsayanukul P; Iemwimangsa N; Klumsathian S; Panthan B; Trachoo O
    BMC Neurol; 2022 Dec; 22(1):461. PubMed ID: 36494631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.
    Iyer A; Appleton R
    Paediatr Drugs; 2016 Oct; 18(5):357-66. PubMed ID: 27541933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.